AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: David Saito-Chung
Accredo Health has moved virtually sideways since last December. Lately, the stock has bounced between around 30 and 40. It's 9% off its high.
A good stock will tighten up in price, and volume will shrink toward the right end of the base. Watch to see if Accredo's price action tightens up.
Accredo's Relative Strength line has trekked to new high ground, a bullish sign. This means the stock is already outperforming the S&P 500, a proxy for the market.
The firm specializes in pharmacy-related services for patients with chronic, costly diseases. Almost 90% of its revenue comes from treatments for multiple sclerosis, hemophilia and Gaucher disease, according to a story in The New America on Dec. 22 last year.
Earnings have grown 38% to 56% from year-ago levels in the past four quarters. Sales ...